NO20065441L - Fremgangsmate for fremstilling av atazanavir-bisulfat og nye varianter - Google Patents

Fremgangsmate for fremstilling av atazanavir-bisulfat og nye varianter

Info

Publication number
NO20065441L
NO20065441L NO20065441A NO20065441A NO20065441L NO 20065441 L NO20065441 L NO 20065441L NO 20065441 A NO20065441 A NO 20065441A NO 20065441 A NO20065441 A NO 20065441A NO 20065441 L NO20065441 L NO 20065441L
Authority
NO
Norway
Prior art keywords
bisulfate
atazanavir
preparation
crystals
atazanavir bisulfate
Prior art date
Application number
NO20065441A
Other languages
English (en)
Other versions
NO341013B1 (no
Inventor
Jack Z Gougoutas
Martha Davidovich
Soojin Kim
Bruce T Lotz
Mary F Malley
Sushil K Srivastava
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35310244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065441(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20065441L publication Critical patent/NO20065441L/no
Publication of NO341013B1 publication Critical patent/NO341013B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/127—Preparation from compounds containing pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det tilveiebringes en fremgangsmåte for fremstilling av HlV-protease-hemmeren atazanavir-bisulfat, hvor en løsning av atazanavir som fri base blir omsatt med konsentrert svovelsyre i en mengde for å reagere med mindre enn ca. 15 vekt% av den frie basen, kimkrystaller av form A-krystaller av atazanavir-bisulfat blir satt til reaksjonsblandingen, og som krystaller av bisulfat-formen blir ytterligere konsentrert svovelsyre tilsatt i mange trinn i økende rater i henhold til en tredjegradsligning, for å bevirke dannelse av form A-krystaller av atazanavir-bisulfat. Det tilveiebringes også en fremgangsmåte for fremstilling av atazanavir-bisulfat som mønster C-materiale. Det tilveiebringes også en ny form av atazanavir-bisulfat som er form E3, som er et meget krystallinsk trietanolatsolvat av bisulfat-saltet fra etanol.
NO20065441A 2004-05-04 2006-11-27 Fremgangsmåte for fremstilling av atazanavirbisulfat,og former derav NO341013B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56804304P 2004-05-04 2004-05-04
US60753304P 2004-09-07 2004-09-07
US11/119,558 US7829720B2 (en) 2004-05-04 2005-05-02 Process for preparing atazanavir bisulfate and novel forms
PCT/US2005/015333 WO2005108349A2 (en) 2004-05-04 2005-05-03 Process for preparing atazanavir bisulfate and novel forms

Publications (2)

Publication Number Publication Date
NO20065441L true NO20065441L (no) 2006-11-27
NO341013B1 NO341013B1 (no) 2017-08-07

Family

ID=35310244

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065441A NO341013B1 (no) 2004-05-04 2006-11-27 Fremgangsmåte for fremstilling av atazanavirbisulfat,og former derav

Country Status (20)

Country Link
US (3) US7829720B2 (no)
EP (3) EP2669273A1 (no)
JP (1) JP5086069B2 (no)
KR (1) KR101153606B1 (no)
AU (2) AU2005240622B2 (no)
BR (1) BRPI0509595B8 (no)
CA (2) CA2565629C (no)
CY (1) CY1116919T1 (no)
DK (1) DK1755596T5 (no)
ES (1) ES2552219T3 (no)
HR (1) HRP20150962T2 (no)
HU (1) HUE026242T2 (no)
IL (1) IL178965A (no)
MX (1) MXPA06012612A (no)
NO (1) NO341013B1 (no)
PL (1) PL1755596T3 (no)
PT (1) PT1755596E (no)
RS (1) RS54284B1 (no)
SI (1) SI1755596T1 (no)
WO (1) WO2005108349A2 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US7829720B2 (en) 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
TWI354569B (en) * 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method
US7642049B2 (en) 2006-06-30 2010-01-05 Bristol-Myers Squibb Company Method for identifying HIV-1 protease inhibitors with reduced metabolic affects through detection of human resistin polymorphisms
PL2003120T3 (pl) 2007-06-12 2010-04-30 Concert Pharmaceuticals Inc Pochodne azapeptydu jako inhibitory proteazy HIV
DE602008005896D1 (de) * 2007-06-22 2011-05-12 Bristol Myers Squibb Co Tablettierte atazanavirhaltige zusammensetzungen
KR20100033378A (ko) * 2007-06-22 2010-03-29 브리스톨-마이어스 스큅 컴퍼니 아타자나비르를 함유하는 정제 조성물
DE602008005462D1 (de) * 2007-06-22 2011-04-21 Bristol Myers Squibb Co Tablettierte atazanavirhaltige zusammensetzungen
DK2170292T3 (da) * 2007-06-22 2014-04-07 Bristol Myers Squibb Holdings Ireland Atazanavirholdige sammensætninger i tabletform
WO2010079497A2 (en) * 2009-01-12 2010-07-15 Hetero Research Foundation Novel polymorph of atazanavir sulfate
WO2011027324A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Polymorphic forms of atazanavir sulfate
AU2010313571B2 (en) 2009-10-26 2014-07-31 Merck Sharp & Dohme Llc Solid pharmaceutical compositions containing an integrase inhibitor
WO2011127244A2 (en) 2010-04-09 2011-10-13 Bristol-Myers Squibb Company ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT
WO2012041488A1 (en) 2010-09-28 2012-04-05 Ratiopharm Gmbh Dry processing of atazanavir
WO2013014633A1 (en) 2011-07-27 2013-01-31 Ranbaxy Laboratories Limited Process for preparation of atazanavir or its bisulfate salt
US8461347B2 (en) 2011-08-05 2013-06-11 Scinopharm Taiwan, Ltd. Process for preparing form A of atazanavir sulfate
US9382207B2 (en) 2012-08-24 2016-07-05 Laurus Labs Private Limited Process for the preparation of atazanavir bisulfate
WO2014036690A1 (zh) * 2012-09-04 2014-03-13 上海迪赛诺化学制药有限公司 制备阿扎那韦硫酸氢盐a型结晶的方法
CA2900705A1 (en) 2013-02-12 2014-08-21 Cipla Limited Process for preparing atazanavir sulphate
CN115215792A (zh) * 2022-06-27 2022-10-21 江西富祥药业股份有限公司 一种制备阿扎那韦或其硫酸盐的方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US658435A (en) * 1900-03-22 1900-09-25 William T Ginn Coal-digger.
US4026897A (en) 1974-01-31 1977-05-31 Otsuka Pharmaceutical Company 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives
US3980637A (en) 1975-03-17 1976-09-14 Bristol-Myers Company Production of amoxicillin
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
JPS6186211A (ja) 1984-10-04 1986-05-01 日本碍子株式会社 セラミックス複合構造体及びその製造法
FR2623810B2 (fr) * 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
CA2068402C (en) * 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
US5428048A (en) * 1993-11-08 1995-06-27 American Home Products Corporation Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents
GB9407386D0 (en) * 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
KR100486051B1 (ko) * 1996-04-22 2005-09-09 노파르티스 아게 항바이러스활성헤테로시클릭아자헥산유도체
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
GB9715896D0 (en) 1997-07-28 1997-10-01 Sca Packaging Ltd Containers
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
FR2779726B1 (fr) * 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
WO2000056719A1 (en) * 1999-03-22 2000-09-28 Bristol-Myers Squibb Company FUSED PYRIDOPYRIDAZINE INHIBITORS OF cGMP PHOSPHODIESTERASE
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
CA2390557A1 (en) 1999-11-11 2001-05-17 Kyorin Pharmaceutical Co., Ltd. Solid preparations for oral use
DE60124861T2 (de) 2000-01-21 2007-05-10 Novartis Ag Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
US6254888B1 (en) * 2000-01-28 2001-07-03 Boehringer Ingelheim Pharmaceuticals, Inc. Method for coating pharmaceutical dosage forms
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
YU34501A (sh) 2000-05-26 2003-10-31 Pfizer Products Inc. Postupak reaktivne kristalizacije radi povećanja veličine čestica
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US6670344B2 (en) * 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US6946146B2 (en) 2001-04-18 2005-09-20 Nostrum Pharmaceuticals Inc. Coating for a sustained release pharmaceutical composition
BR0306928A (pt) 2002-01-15 2004-11-09 Ranbaxy Lab Ltd Composições farmacêuticas estáveis compreendendo inibidores de enzimas conversoras de angiotensina (ace)
KR100456833B1 (ko) 2002-08-01 2004-11-10 주식회사 대웅 아목시실린 및 클라불라네이트를 함유하는 유핵정
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US7829720B2 (en) 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US20050288343A1 (en) * 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
TWI354569B (en) * 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method

Also Published As

Publication number Publication date
EP1755596A2 (en) 2007-02-28
EP1755596B1 (en) 2015-08-12
BRPI0509595B1 (pt) 2019-05-14
EP2669273A1 (en) 2013-12-04
IL178965A (en) 2011-05-31
BRPI0509595A (pt) 2007-10-16
AU2005240622B2 (en) 2010-02-11
CA2565629A1 (en) 2005-11-17
EP2980074A1 (en) 2016-02-03
AU2010201538A1 (en) 2010-05-13
WO2005108349A2 (en) 2005-11-17
NO341013B1 (no) 2017-08-07
US20050256202A1 (en) 2005-11-17
IL178965A0 (en) 2007-03-08
KR101153606B1 (ko) 2012-06-11
DK1755596T5 (en) 2016-05-23
BRPI0509595B8 (pt) 2021-05-25
CA2565629C (en) 2012-07-31
CY1116919T1 (el) 2017-04-05
AU2005240622A1 (en) 2005-11-17
MXPA06012612A (es) 2006-12-15
US20090203630A1 (en) 2009-08-13
PL1755596T3 (pl) 2016-04-29
US7829720B2 (en) 2010-11-09
AU2010201538B2 (en) 2012-09-06
CA2777216A1 (en) 2005-11-17
PT1755596E (pt) 2015-11-19
ES2552219T3 (es) 2015-11-26
SI1755596T1 (sl) 2015-10-30
EP1755596B9 (en) 2016-02-10
WO2005108349A3 (en) 2006-11-02
JP2007536245A (ja) 2007-12-13
US8513428B2 (en) 2013-08-20
HRP20150962T1 (en) 2015-10-09
JP5086069B2 (ja) 2012-11-28
DK1755596T3 (en) 2015-11-16
EP1755596A4 (en) 2010-12-29
US20110124689A1 (en) 2011-05-26
RS54284B1 (en) 2016-02-29
HUE026242T2 (en) 2016-06-28
KR20070006935A (ko) 2007-01-11
HRP20150962T2 (hr) 2016-04-08
US7838678B2 (en) 2010-11-23

Similar Documents

Publication Publication Date Title
NO20065441L (no) Fremgangsmate for fremstilling av atazanavir-bisulfat og nye varianter
TW200600498A (en) Process for preparing atazanavir bisulfate and novel forms
NO20074055L (no) Prosesser for a fremstille 4-(fenoksy-5-metylpyrimidin-4-yloksy)piperidin-1-karboksylsyrederivater og relaterte forbindelser
CN101497601B (zh) 伊马替尼的合成方法
Kuang et al. Utilization of the 1, 2, 5-thiadiazolidin-3-one 1, 1 dioxide scaffold in the design of potent inhibitors of serine proteases: SAR studies using carboxylates
MX2008002093A (es) Catalisis para la sintesis de cf3i y cf3cf2i.
Xie et al. Synthesis and evaluation of substituted 3-(pyridin-2-yl) benzenesulfonamide derivatives as potent herbicidal agents
DK1697326T3 (da) Krystalform af en quinolinforbindelse og fremgangsmåde til fremstilling deraf
Pan et al. Design, synthesis and biological activities of Nilotinib derivates as antitumor agents
MD4391C1 (ro) Formă cristalină nouă VII a agomelatinei, procedeu de preparare şi utilizarea acesteia, şi compoziţie farmaceutică care o conţine
US20170283380A1 (en) Intermediate for Synthesizing Paroxetine, Method for Preparing the same, and Uses Thereof
NO20082005L (no) Syntese av renininhibitorer omfattende en cyklotilfoyelsesreaksjon
WO2007105021A3 (en) Duloxetine salts
WO2020134137A1 (zh) 一种r-3-氯丝氨酸甲酯盐酸盐的制备方法
TW201245114A (en) Process for the preparation of pyrazole carboxylic acid amides
TW310262B (no)
DK1725526T3 (da) Fremgangsmåde til fremstilling af pyrrolidinoximer
CN105001163B (zh) 一种四取代咪唑的合成方法
CN106883189A (zh) 用二硒醚、炔酸和叠氮合成含硒的三氮唑类化合物的方法
JP5740042B2 (ja) 化合物、化合物の製造方法、及び化合物の精製方法
Gein et al. Synthesis and Structure (Z)-N-Aryl-2-hydroxy-4-oxo-4-phenylbut-2-enamides
CN106458928A (zh) 含醚性氧原子的全氟烷基取代嘧啶环化合物及其制造方法
CN104003887A (zh) 一种盐酸溴己新的制备方法
JP2017517531A (ja) ピペリジン−４−カルボチオアミドの製造
CN103772308B (zh) 5-氨基-3-(1-乙基-1-甲基丙基)异噁唑中间体的制备方法和异噁草胺的制备方法

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND, CH

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND, CH

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMI, CH